APA (7th ed.) Citation

Mohammadreza Rafati, Hossein Karami, Bita Lashtoo-Aghaee, Bahareh Lashtoo-Aghaee, Mojdeh Dabirian, & Razieh Avan. (2022). Two trade names of deferasirox (Osveral® and Exjade®) in reduction of iron overload parameters in major beta-thalassemia patients: A randomized open labeled clinical trial. Babol University of Medical Sciences.

Chicago Style (17th ed.) Citation

Mohammadreza Rafati, Hossein Karami, Bita Lashtoo-Aghaee, Bahareh Lashtoo-Aghaee, Mojdeh Dabirian, and Razieh Avan. Two Trade Names of Deferasirox (Osveral® and Exjade®) in Reduction of Iron Overload Parameters in Major Beta-thalassemia Patients: A Randomized Open Labeled Clinical Trial. Babol University of Medical Sciences, 2022.

MLA (9th ed.) Citation

Mohammadreza Rafati, et al. Two Trade Names of Deferasirox (Osveral® and Exjade®) in Reduction of Iron Overload Parameters in Major Beta-thalassemia Patients: A Randomized Open Labeled Clinical Trial. Babol University of Medical Sciences, 2022.